Neimeth International Pharmaceutical Plc (NEIMET.ng) Q12023 Interim Report

Neimeth International Pharmaceutical Plc (NEIMET.ng) listed on the Nigerian Stock Exchange under the Pharmaceuticals sector has released it’s 2023 interim results for the first quarter.

For more information about Neimeth International Pharmaceutical Plc (NEIMET.ng) reports, abridged reports, interim earnings results and earnings presentations visit the Neimeth International Pharmaceutical Plc (NEIMET.ng) company page on AfricanFinancials.

Indicative Share Trading Liquidity

The total indicative share trading liquidity for Neimeth International Pharmaceutical Plc (NEIMET.ng) in the past 12 months, as of 2nd February 2023, is US$248.63K (NGN104.9M). An average of US$20.72K (NGN8.74M) per month.

Neimeth International Pharmaceutical Plc 2023 interim results for the first quarter

Company Profile

Neimeth International Pharmaceuticals Plc manufactures and markets a range of Pfizer pharmaceutical and animal health products in Nigeria. The company has one of the most modern pharmaceutical manufacturing plants in West Africa located in Oregun, Lagos. Products in its ethical range include the flagship product CIKLAVIT for the treatment of sickle disease; and Normoretic, Flexodene and Tiocosid. Products in its consumer range include well-known brands such as NCP, Pyrantin, Obron-6, Homtamin G and Pancemol. Products in its animal health care and veterinary range treatments for diseases in poultry and cattle. Neimeth International Pharmaceuticals has business interests in Ghana, Sierra Leone, Liberia and the Gambia. Its company head office is in Lagos, Nigeria. Neimeth International Pharmaceuticals Plc is listed on the Nigerian Stock Exchange